Conference
A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191
Abstract
Abstract
Background:Although outcomes for patients with multiple myeloma (MM) have improved, it remains an incurable malignancy for which new therapies are needed. Aurora kinases are overexpressed in MM. Inhibition of Aurora A kinase, a key component of the centrosome, in MM cell lines induces apoptotic cell death. Inhibition of Aurora B, a chromosome passenger protein, has therapeutic effects against myeloma lines, primary …
Authors
Hay AE; Murugesan A; DiPasquale AM; Kouroukis T; Sandhu I; Kukreti V; Bahlis NJ; Lategan J; Reece DE; Lyons JF
Volume
124
Publisher
American Society of Hematology
Publication Date
December 6, 2014
DOI
10.1182/blood.v124.21.5734.5734
Conference proceedings
Blood
Issue
21
ISSN
0006-4971